Saltar al contenido
Merck
  • Increased protein aggregation in Zucker diabetic fatty rat brain: identification of key mechanistic targets and the therapeutic application of hydrogen sulfide.

Increased protein aggregation in Zucker diabetic fatty rat brain: identification of key mechanistic targets and the therapeutic application of hydrogen sulfide.

BMC cell biology (2014-01-08)
Fatemeh Talaei, Veroniek M Van Praag, Mahdi H Shishavan, Sjoerd W Landheer, Henk Buikema, Robert H Henning
RESUMEN

Diabetes and particularly high blood glucose levels are implicated in neurodegeneration. One of the hallmarks of neurodegeneration is protein aggregation. We investigated the presence of protein aggregation in the frontal brain of Zucker diabetic fatty (ZDF) rats, an animal model for diabetes. Further, the effect of NaHS in suppressing protein aggregation in cultured brain slices from ZDF was assessed. The levels of protein synthesis, protein/gene expression, autophagy and anti-oxidant defense were evaluated in ZDF and control (Lean) brains.Compared to Lean, ZDF brains displayed a significant increase in protein aggregates, p-tau, fibronectin expression and protein glycosylation. Increased phosphorylation of mTOR and S6 ribosomal protein in ZDF indicated higher protein synthesis, while the increase in ubiquitinated proteins and LC3-I in ZDF brains accompanied by lower LC3-II expression and LC3-II/LC3-I levels indicated the blockage of proteolytic pathways. CBS (cystathionine beta synthase) protein and mRNA expression and thiol group levels in ZDF brains were lower compared to Lean. ZDF brains show a higher level of reactive oxygen species. In vitro NaHS treatment normalized proteostasis while counteracting oxidative stress. Our data demonstrate increased protein synthesis and aggregation in the diabetic ZDF rat brain, which was reversible by NaHS treatment.This is the first report on the potential use of NaHS as a novel strategy against protein aggregation in diabetic brain.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC)
Sigma-Aldrich
D-(+)-Glucosa, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Dextrosa, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
Ácido 5,5′-ditiobis(2-nitrobenzoico), ≥98%, BioReagent, suitable for determination of sulfhydryl groups
Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC), BioXtra
USP
D-(+)-Glucosa, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ácido 5,5′-ditiobis(2-nitrobenzoico), ReagentPlus®, 99%
Sigma-Aldrich
Peróxido de hidrógeno solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
D-(+)-Glucosa, ACS reagent
Sigma-Aldrich
D-(+)-Glucosa, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Millipore
Peróxido de hidrógeno solution, 3%, suitable for microbiology
Supelco
D-(+)-Glucosa, analytical standard
Supelco
D-(+)-Glucosa, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-(+)-Glucosa, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
3-Amino-9-ethylcarbazole, ≥95% (HPLC), powder
Sigma-Aldrich
3-Amino-9-ethylcarbazole, tablet
Sigma-Aldrich
D-(+)-Glucosa, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D-(+)-Glucosa, 99.9 atom % 16O, 99.9 atom % 12C
Sigma-Aldrich
D-(+)-Glucosa, tested according to Ph. Eur.
Sigma-Aldrich
mTOR phosphorylation Pathway Explorer Antibody MiniPack, This Antibody pack of Anti-mTOR antibodies contains Anti-phospho-mTOR Antibody(Ser2481), Anti-phospho-mTOR Antibody (Thr2446), Anti-phospho-mTOR (Ser2448).